See more : Jammin Java Corp. (JAMN) Income Statement Analysis – Financial Results
Complete financial analysis of C-Bond Systems, Inc. (CBNT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of C-Bond Systems, Inc., a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
- Lan Fa Textile Co.,Ltd. (1459.TW) Income Statement Analysis – Financial Results
- Gseven Co., Ltd. (2937.TWO) Income Statement Analysis – Financial Results
- A2B Australia Limited (A2B.AX) Income Statement Analysis – Financial Results
- Schaffer Corporation Limited (SFC.AX) Income Statement Analysis – Financial Results
- Vector Inc. (6058.T) Income Statement Analysis – Financial Results
C-Bond Systems, Inc. (CBNT)
About C-Bond Systems, Inc.
C-Bond Systems, Inc., a nanotechnology company, owns, develops, manufactures, and sells patented C-Bond technology in the United Sates. The company's products include C-Bond NanoShield, a patented nanotechnology windshield glass strengthening and hydrophobic all-in-one performance system to improve windshield safety and performance; C-Bond Secure, a patented non-toxic water-based nanotechnology solution to improve the strength of architectural glass and performance properties of window film-to-glass products; and C-Bond BRS, a patented nanotechnology ballistic-resistant film system that increases the structural integrity of glass. It also distributes MB-10 and Vimoba disinfectant tablets to school facilities and buses, dealerships, global distribution network, and service providers, as well as the transportation detailing, automotive, trucking, RV, rental agency, service vehicles, mass transit, golf carts, aviation, train, and marine markets. The company was founded in 2013 and is headquartered in Houston, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.49M | 2.23M | 1.48M | 658.43K | 602.64K | 382.24K | 405.42K | 723.61K | 0.00 | 0.00 | 77.70K | 85.12K | 105.00K | 124.77K | 124.64K | 77.84K |
| Cost of Revenue | 1.18M | 954.40K | 657.30K | 242.51K | 121.97K | 83.38K | 7.96M | 2.28K | 4.65K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.31M | 1.28M | 819.53K | 415.93K | 480.67K | 298.86K | -7.56M | 721.33K | -4.65K | 0.00 | 77.70K | 85.12K | 105.00K | 124.77K | 124.64K | 77.84K |
| Gross Profit Ratio | 52.54% | 57.25% | 55.49% | 63.17% | 79.76% | 78.19% | -1,863.73% | 99.68% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | 0.00 | -3.25K | 16.63K | 31.06K | 258.29K | 214.11K | 220.52K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.27M | 4.47M | 7.83M | 4.88M | 6.81M | 9.31M | 559.98K | 636.60K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 31.74K | 69.74K | 65.63K | 46.28K | 36.24K | 51.72K | -502.83K | -583.60K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.24M | 4.47M | 7.83M | 4.88M | 6.81M | 9.31M | 57.14K | 53.00K | 63.50K | 52.49K | 71.97K | 58.68K | 57.45K | 58.77K | 113.46K | 127.44K |
| Other Expenses | 0.00 | 1.89M | 5.50M | 6.57K | 5.12M | -200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | -747.89K | 4.47M | 7.83M | 4.89M | 6.84M | 9.57M | 57.14K | 53.00K | 63.50K | 52.49K | 71.97K | 58.68K | 57.45K | 58.77K | 113.46K | 127.44K |
| Cost & Expenses | 433.09K | 5.43M | 8.49M | 5.14M | 6.96M | 9.65M | 57.14K | 53.00K | 63.50K | 52.49K | 71.97K | 58.68K | 57.45K | 58.77K | 113.46K | 127.44K |
| Interest Income | 0.00 | 1.62M | 282.96K | 751.18K | 343.08K | 0.00 | 125.00 | 140.00 | 123.00 | 129.00 | 173.00 | 216.00 | 431.00 | 936.00 | 3.38K | 8.47K |
| Interest Expense | 475.43K | 1.62M | 282.96K | 751.18K | 343.08K | 53.14K | 125.00 | 140.00 | 123.00 | 129.00 | 173.00 | 216.00 | 431.00 | 936.00 | 3.38K | 8.47K |
| Depreciation & Amortization | 88.86K | 90.30K | 45.60K | 14.49K | 24.63K | 33.72K | 38.30K | 2.28K | 4.65K | 4.65K | 2.37K | 0.00 | 3.58K | 3.27K | 2.90K | 2.85K |
| EBITDA | 2.45M | -3.45M | -6.80M | -3.67M | -6.87M | -9.82M | -8.25M | -50.58K | -58.72K | -47.71K | 8.10K | 26.66K | 51.13K | 69.27K | 14.08K | -38.28K |
| EBITDA Ratio | 98.50% | -139.00% | -471.56% | -677.81% | -1,051.05% | -2,415.83% | -14.09% | -7.01% | 0.00% | 0.00% | 10.43% | 31.06% | 48.69% | 55.52% | 11.29% | -60.07% |
| Operating Income | 2.06M | -3.19M | -7.01M | -4.48M | -6.36M | -9.27M | -57.14K | -53.00K | -63.50K | -52.49K | 5.73K | 26.44K | 47.55K | 66.00K | 11.18K | -49.61K |
| Operating Income Ratio | 82.60% | -142.99% | -474.67% | -679.95% | -1,055.13% | -2,424.66% | -14.09% | -7.32% | 0.00% | 0.00% | 7.37% | 31.06% | 45.28% | 52.90% | 8.97% | -63.73% |
| Total Other Income/Expenses | -168.60K | -1.96M | -118.74K | 42.59K | -882.13K | -636.62K | -8.01K | 140.00 | 123.00 | 129.00 | 173.00 | 216.00 | 431.00 | 936.00 | 3.38K | 8.47K |
| Income Before Tax | 1.89M | -5.16M | -7.13M | -4.43M | -7.24M | -9.90M | -57.02K | -52.86K | -63.38K | -52.36K | 5.90K | 26.66K | 47.98K | 66.94K | 14.55K | -41.13K |
| Income Before Tax Ratio | 75.82% | -230.96% | -482.71% | -673.49% | -1,201.51% | -2,591.20% | -14.06% | -7.30% | 0.00% | 0.00% | 7.59% | 31.31% | 45.69% | 53.65% | 11.68% | -52.84% |
| Income Tax Expense | 0.00 | 305.38K | 298.48K | 751.18K | 343.08K | 583.48K | -250.00 | -280.00 | -246.00 | 457.00 | -152.00 | 5.04K | 9.09K | 2.08K | -6.75K | -16.95K |
| Net Income | 1.90M | -5.46M | -7.43M | -5.19M | -7.58M | -9.90M | -57.02K | -52.86K | -63.38K | -52.82K | 6.05K | 21.61K | 38.89K | 64.86K | 14.55K | -41.13K |
| Net Income Ratio | 76.18% | -244.64% | -502.93% | -787.57% | -1,258.44% | -2,591.20% | -14.06% | -7.30% | 0.00% | 0.00% | 7.79% | 25.39% | 37.04% | 51.98% | 11.68% | -52.84% |
| EPS | 0.00 | -0.02 | -0.03 | -0.03 | -0.08 | -0.14 | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | -0.02 | -0.03 | -0.03 | -0.08 | -0.14 | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 490.11M | 308.12M | 254.30M | 172.98M | 94.24M | 68.52M | 45.28M | 9.11M | 9.11M | 9.11M | 9.11M | 9.11M | 9.11M | 9.11M | 9.11M | 9.11M |
| Weighted Avg Shares Out (Dil) | 2.52B | 308.12M | 254.30M | 172.98M | 94.24M | 68.52M | 45.28M | 9.11M | 9.11M | 9.11M | 9.11M | 9.11M | 9.11M | 9.11M | 9.11M | 9.11M |
C-Bond Systems' CEO Scott R. Silverman and World-Renowned Chemist and Nanotechnology Expert Professor Andrew R.
C-Bond's EPA Registered MB-10 Tablets Can Directly Address President Biden's Call to Properly Sanitize Schools for Full Reopening
C-Bond Ballistic-Resistant System in Initial Trial with Leading Provider of Custom Structures for a Top Mass Retailer
C-Bond Systems' MB-10 Tablets Receive EPA Label Use Designation for Transportation Applications in the Fight Against COVID-19
C-Bond Ballistic-Resistant System Selected by another Texas School District to Protect Students and Faculty
C-Bond Systems Provides 2021 Annual Revenue Guidance of $2.1M, Signifying Over 150% Growth
Source: https://incomestatements.info
Category: Stock Reports